Prof Sherene Loi
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
805 Scholarly works
44 Projects
HIGHLIGHTS
2026
Journal article
Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
DOI: 10.1038/s41467-026-72956-x2026
Journal article
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial
DOI: 10.1016/S1470-2045(26)00247-02026
Research grants (ARC, NHMRC, MRFF)
Innovating in Breast Cancer Immunology Treatment and Prevention
2022
Journal article
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
DOI: 10.1038/s43018-022-00413-x2021
Journal article
Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
DOI: 10.1093/jnci/djab1112018
Research Grant
Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
2018
Research grants (other domestic)
2018 NBCF Endowed Chair Program
RECENT SCHOLARLY WORKS
2026
Journal article
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group
DOI: 10.1016/S1470-2045(26)00255-X2026
Journal article
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study
DOI: 10.1016/S1470-2045(26)00339-62026
Journal article
Germline BRCA1 pathogenic variants and T cell dysfunction
DOI: 10.1016/j.iotech.2026.1016012026
Journal article
Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
DOI: 10.1016/j.esmoop.2026.1083162026
Journal article
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
DOI: 10.1016/j.annonc.2026.04.0112026
Journal article
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial
DOI: 10.1093/jnci/djag0952026
Journal article
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
DOI: 10.1038/s41467-026-75660-y2026
Journal article
Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies.
DOI: 10.1093/jnci/djag244